论文部分内容阅读
目的 探讨应用卵巢癌抗原 CP2 及卵巢癌抗独特型单克隆抗体 6 B1 1 Ab2 进行血清中相关抗体检测的可行性及临床应用价值 .方法 应用 EL ISA法对 95例恶性卵巢肿瘤、40例良性卵巢肿瘤及 9例子宫内膜异位症患者血清进行卵巢癌相关抗原及抗体的检测 ,并以 5 0例正常女性为对照 .结果 非粘液性卵巢上皮癌抗原阳性率为 10 0 % ,抗体阳性率为 6 6 .7% ,高于粘液性卵巢上皮癌、非上皮性卵巢恶性肿瘤及生殖系统其他恶性肿瘤 ,并且明显高于卵巢良性肿瘤 (P<0 .0 1) .结论 卵巢癌相关抗原及抗体的检测对临床诊断及辅助鉴别诊断有一定实用价值
OBJECTIVE: To investigate the feasibility and clinical value of using serum anti-idiotypic monoclonal antibody 6 B1 1 Ab2 as ovarian cancer anti-idiotypic antibody CP2 as a marker.Methods Ninety-five cases of malignant ovarian tumor, 40 cases of benign ovarian Tumor and 9 cases of endometriosis serum of patients with ovarian cancer-related antigen and antibody detection, and 50 normal women as a control.Results The positive rate of non-mucoid ovarian epithelial carcinoma antigen was 100%, the positive rate of antibody Which was higher than that of mucinous epithelial ovarian cancer, non-epithelial ovarian cancer and other malignant tumors of the reproductive system and was significantly higher than that of benign ovarian tumors (P0.01) .Conclusion The expression of ovarian cancer-associated antigen Antibody detection of clinical diagnosis and auxiliary differential diagnosis have some practical value